179
Views
6
CrossRef citations to date
0
Altmetric
Review

Recent advances in the development of asenapine formulations

, &
Pages 1377-1393 | Received 02 May 2020, Accepted 02 Jul 2020, Published online: 16 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sharon Taub, Amir Krivoy, Eromona Whiskey & Sukhi S. Shergill. (2022) New approaches to antipsychotic medication adherence – safety, tolerability and acceptability. Expert Opinion on Drug Safety 21:4, pages 517-524.
Read now

Articles from other publishers (4)

Shoujun Ren, Chao Liu, Yutong Sun, Yang Zhang, Jiuheng Ruan & Liang Fang. (2023) Formulation Development and Molecular Mechanism Characterization of Long-Acting Patches of Asenapine for Efficient Delivery by Combining API-ILs Strategy and Controlled-Release Polymers. Journal of Pharmaceutical Sciences 112:7, pages 1850-1862.
Crossref
Yuanlong Sun, Na Hu, Gaofeng Chen, Yanjie Wang, Yiyang Hu, Maojun Ge & Yu Zhao. (2022) Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 23:1.
Crossref
Young-A Heo. (2021) Asenapine transdermal delivery system (Secuado®) in schizophrenia: a profile of its use in the USA. Drugs & Therapy Perspectives 37:6, pages 229-235.
Crossref
Katsumi Suzuki, Mariacristina Castelli, Marina Komaroff, Brittney Starling, Takaaki Terahara & Leslie Citrome. (2021) Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070). Journal of Clinical Psychopharmacology 41:3, pages 286-294.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.